Altimmune, Inc. (ALT) Reaches $0.61 52-Week Low; Antero Resources (AR)’s Sentiment Is 1.32

May 7, 2018 - By Marie Mckinney

Antero Resources Corporation (NYSE:AR) Logo

Antero Resources Corp (AR) investors sentiment increased to 1.32 in 2017 Q4. It’s up 0.15, from 1.17 in 2017Q3. The ratio improved, as 139 hedge funds increased and started new positions, while 105 cut down and sold stock positions in Antero Resources Corp. The hedge funds in our database reported: 282.31 million shares, down from 291.74 million shares in 2017Q3. Also, the number of hedge funds holding Antero Resources Corp in top ten positions increased from 10 to 12 for an increase of 2. Sold All: 33 Reduced: 72 Increased: 93 New Position: 46.

The stock of Altimmune, Inc. (NASDAQ:ALT) hit a new 52-week low and has $0.56 target or 8.00% below today’s $0.61 share price. The 5 months bearish chart indicates high risk for the $10.95M company. The 1-year low was reported on May, 7 by If the $0.56 price target is reached, the company will be worth $876,240 less. The stock decreased 3.97% or $0.025 during the last trading session, reaching $0.605. About 415,676 shares traded or 8.62% up from the average. Altimmune, Inc. (NASDAQ:ALT) has declined 84.57% since May 7, 2017 and is downtrending. It has underperformed by 96.12% the S&P500.

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, creates and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer. The company has market cap of $10.95 million. The firm develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. It currently has negative earnings. The Company’s preclinical stage products include NasoShield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and Oncosyn, an immunotherapeutic for treating solid cancer indications, such as lung, colorectal, melanoma, breast, ovarian, and others.

Another recent and important Altimmune, Inc. (NASDAQ:ALT) news was published by which published an article titled: “Benzinga’s Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down” on May 04, 2018.

Antero Resources Corporation, an independent oil and natural gas company, acquires, explores, produces, and develops natural gas, natural gas liquids, and oil properties in the United States. The company has market cap of $5.86 billion. As of December 31, 2016, the firm had 616,000 net acres of gas and oil properties located in the Appalachian Basin in West Virginia, Ohio, and Pennsylvania. It has a 9.53 P/E ratio. It also owned and operated 213 miles of gas gathering pipelines in the Marcellus Shale; and 113 miles of low-pressure, high-pressure, and condensate pipelines in the Utica Shale.

The stock increased 1.71% or $0.31 during the last trading session, reaching $18.48. About 1.58 million shares traded. Antero Resources Corporation (AR) has declined 15.07% since May 7, 2017 and is downtrending. It has underperformed by 26.62% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 2 selling transactions for $97,325 activity.

Ratings analysis reveals 100% of Antero Resources’s analysts are positive. Out of 5 Wall Street analysts rating Antero Resources, 5 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. AR was included in 5 notes of analysts from October 28, 2016. The firm has “Buy” rating given on Monday, November 21 by Deutsche Bank. The company was upgraded on Friday, October 28 by Susquehanna. Piper Jaffray upgraded Antero Resources Corporation (NYSE:AR) on Friday, January 13 to “Overweight” rating. The firm has “Accumulate” rating given on Friday, December 9 by Seaport Global Securities. Raymond James upgraded Antero Resources Corporation (NYSE:AR) on Tuesday, January 3 to “Strong Buy” rating.

Analysts await Antero Resources Corporation (NYSE:AR) to report earnings on May, 14. They expect $0.28 EPS, up 55.56% or $0.10 from last year’s $0.18 per share. AR’s profit will be $88.77M for 16.50 P/E if the $0.28 EPS becomes a reality. After $0.19 actual EPS reported by Antero Resources Corporation for the previous quarter, Wall Street now forecasts 47.37% EPS growth.

Yale University holds 25.43% of its portfolio in Antero Resources Corporation for 4.07 million shares. Sailingstone Capital Partners Llc owns 34.91 million shares or 19.2% of their US portfolio. Moreover, Warburg Pincus Llc has 17.94% invested in the company for 46.61 million shares. The Texas-based Caymus Capital Partners L.P. has invested 10.76% in the stock. Brave Warrior Advisors Llc, a New York-based fund reported 11.04 million shares.

Antero Resources Corporation (NYSE:AR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: